Arginine deiminase: A potential inhibitor of angiogenesis and tumour growth

I. S. Park, S. W. Kang, Y. J. Shin, K. Y. Chae, M. O. Park, M. Y. Kim, D. N. Wheatley, Bon Hong Min

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Hydrolysis of plasma arginine to citrulline by arginine deiminase (ADI) was recently shown to suppress lipopolysaccharide-induced nitric oxide (NO) synthesis. Since arginine is the precursor of NO, and the latter modulates angiogenesis, we explored whether ADI treatment significantly affected tube-like (capillary) formation of human umbilical vein endothelial cells. Inhibition occurred in a dose-dependent manner, both in the chorioallantoic membrane and the murine Matrigel plug assay. Inhibition of angiogenesis by ADI was reversed when a surplus of exogenous arginine was provided, indicating that its antiangiogenic effect is primarily due to arginine depletion, although other pathways of interference are not entirely excluded. Arginine deiminase is also shown to be as a potent inhibitor of tumour growth in vitro as in vivo, being effective at nanogram quantities per millilitre in CHO and HeLa cells. Thus, it could be highly beneficial in cancer therapy because of its two-pronged attack as both an antiproliferative and an antiangiogenic agent.

Original languageEnglish
Pages (from-to)907-914
Number of pages8
JournalBritish Journal of Cancer
Volume89
Issue number5
DOIs
Publication statusPublished - 2003 Sep 1

Fingerprint

Angiogenesis Inhibitors
Arginine
Growth
Neoplasms
Nitric Oxide
Chorioallantoic Membrane
Growth Inhibitors
Citrulline
CHO Cells
Human Umbilical Vein Endothelial Cells
HeLa Cells
Lipopolysaccharides
Hydrolysis
arginine deiminase
Therapeutics

Keywords

  • Antiangiogenic
  • Antiproliferative
  • Arginine
  • Arginine deiminase
  • Citrulline
  • NO

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Park, I. S., Kang, S. W., Shin, Y. J., Chae, K. Y., Park, M. O., Kim, M. Y., ... Min, B. H. (2003). Arginine deiminase: A potential inhibitor of angiogenesis and tumour growth. British Journal of Cancer, 89(5), 907-914. https://doi.org/10.1038/sj.bjc.6601181

Arginine deiminase : A potential inhibitor of angiogenesis and tumour growth. / Park, I. S.; Kang, S. W.; Shin, Y. J.; Chae, K. Y.; Park, M. O.; Kim, M. Y.; Wheatley, D. N.; Min, Bon Hong.

In: British Journal of Cancer, Vol. 89, No. 5, 01.09.2003, p. 907-914.

Research output: Contribution to journalArticle

Park, IS, Kang, SW, Shin, YJ, Chae, KY, Park, MO, Kim, MY, Wheatley, DN & Min, BH 2003, 'Arginine deiminase: A potential inhibitor of angiogenesis and tumour growth', British Journal of Cancer, vol. 89, no. 5, pp. 907-914. https://doi.org/10.1038/sj.bjc.6601181
Park, I. S. ; Kang, S. W. ; Shin, Y. J. ; Chae, K. Y. ; Park, M. O. ; Kim, M. Y. ; Wheatley, D. N. ; Min, Bon Hong. / Arginine deiminase : A potential inhibitor of angiogenesis and tumour growth. In: British Journal of Cancer. 2003 ; Vol. 89, No. 5. pp. 907-914.
@article{b8ba3076c5544b3cbce3cf622fc08fa9,
title = "Arginine deiminase: A potential inhibitor of angiogenesis and tumour growth",
abstract = "Hydrolysis of plasma arginine to citrulline by arginine deiminase (ADI) was recently shown to suppress lipopolysaccharide-induced nitric oxide (NO) synthesis. Since arginine is the precursor of NO, and the latter modulates angiogenesis, we explored whether ADI treatment significantly affected tube-like (capillary) formation of human umbilical vein endothelial cells. Inhibition occurred in a dose-dependent manner, both in the chorioallantoic membrane and the murine Matrigel plug assay. Inhibition of angiogenesis by ADI was reversed when a surplus of exogenous arginine was provided, indicating that its antiangiogenic effect is primarily due to arginine depletion, although other pathways of interference are not entirely excluded. Arginine deiminase is also shown to be as a potent inhibitor of tumour growth in vitro as in vivo, being effective at nanogram quantities per millilitre in CHO and HeLa cells. Thus, it could be highly beneficial in cancer therapy because of its two-pronged attack as both an antiproliferative and an antiangiogenic agent.",
keywords = "Antiangiogenic, Antiproliferative, Arginine, Arginine deiminase, Citrulline, NO",
author = "Park, {I. S.} and Kang, {S. W.} and Shin, {Y. J.} and Chae, {K. Y.} and Park, {M. O.} and Kim, {M. Y.} and Wheatley, {D. N.} and Min, {Bon Hong}",
year = "2003",
month = "9",
day = "1",
doi = "10.1038/sj.bjc.6601181",
language = "English",
volume = "89",
pages = "907--914",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Arginine deiminase

T2 - A potential inhibitor of angiogenesis and tumour growth

AU - Park, I. S.

AU - Kang, S. W.

AU - Shin, Y. J.

AU - Chae, K. Y.

AU - Park, M. O.

AU - Kim, M. Y.

AU - Wheatley, D. N.

AU - Min, Bon Hong

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Hydrolysis of plasma arginine to citrulline by arginine deiminase (ADI) was recently shown to suppress lipopolysaccharide-induced nitric oxide (NO) synthesis. Since arginine is the precursor of NO, and the latter modulates angiogenesis, we explored whether ADI treatment significantly affected tube-like (capillary) formation of human umbilical vein endothelial cells. Inhibition occurred in a dose-dependent manner, both in the chorioallantoic membrane and the murine Matrigel plug assay. Inhibition of angiogenesis by ADI was reversed when a surplus of exogenous arginine was provided, indicating that its antiangiogenic effect is primarily due to arginine depletion, although other pathways of interference are not entirely excluded. Arginine deiminase is also shown to be as a potent inhibitor of tumour growth in vitro as in vivo, being effective at nanogram quantities per millilitre in CHO and HeLa cells. Thus, it could be highly beneficial in cancer therapy because of its two-pronged attack as both an antiproliferative and an antiangiogenic agent.

AB - Hydrolysis of plasma arginine to citrulline by arginine deiminase (ADI) was recently shown to suppress lipopolysaccharide-induced nitric oxide (NO) synthesis. Since arginine is the precursor of NO, and the latter modulates angiogenesis, we explored whether ADI treatment significantly affected tube-like (capillary) formation of human umbilical vein endothelial cells. Inhibition occurred in a dose-dependent manner, both in the chorioallantoic membrane and the murine Matrigel plug assay. Inhibition of angiogenesis by ADI was reversed when a surplus of exogenous arginine was provided, indicating that its antiangiogenic effect is primarily due to arginine depletion, although other pathways of interference are not entirely excluded. Arginine deiminase is also shown to be as a potent inhibitor of tumour growth in vitro as in vivo, being effective at nanogram quantities per millilitre in CHO and HeLa cells. Thus, it could be highly beneficial in cancer therapy because of its two-pronged attack as both an antiproliferative and an antiangiogenic agent.

KW - Antiangiogenic

KW - Antiproliferative

KW - Arginine

KW - Arginine deiminase

KW - Citrulline

KW - NO

UR - http://www.scopus.com/inward/record.url?scp=0141841786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141841786&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601181

DO - 10.1038/sj.bjc.6601181

M3 - Article

C2 - 12942125

AN - SCOPUS:0141841786

VL - 89

SP - 907

EP - 914

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -